News | Proton Therapy | May 25, 2018

More Than 60 Percent of Patients Seeking Proton Therapy Initially Denied Coverage

Alliance for Proton Therapy Access launches grassroots campaign calling for state insurance commissioners to fix insurance process

More Than 60 Percent of Patients Seeking Proton Therapy Initially Denied Coverage

May 25, 2018 — The Alliance for Proton Therapy Access has released a national report revealing the heavy emotional and financial burden that many cancer patients endure when trying to get their insurer’s approval for physician-recommended proton radiation therapy. The report – Cancer Care Denied: The Broken State of Patient Access to Proton Therapy – calls on insurance commissioners in all 50 states to adopt and enforce the principles of a Cancer Patients’ Timely Treatment Bill of Rights and hold insurers accountable for providing fair, timely and transparent access to cancer treatment.

According to patient data provided by several proton therapy centers, nearly two-thirds (63 percent) of cancer patients aged 18 to 64 whose physicians recommend proton therapy as the best course of treatment for their disease are initially denied by their insurer. The report reveals that patients and their physicians are sometimes successful in reversing the initial denial, but time spent waiting – and delaying treatment – averages nearly three weeks (13 working days). In the end, proton therapy is denied more than four times out of ten (42 percent) and it takes an average of more than five weeks (27 working days) to receive that final denial.

“When dealing with the enormity of a cancer diagnosis, private health insurers are adding undue physical, emotional and financial stress on patients. They are denying payment, dragging patients, their families and their doctors through lengthy appeals processes, and delaying access to treatment — seemingly in a systematic and intentional manner,” said Daniel E. Smith, executive director of the alliance. “Unfortunately, delay and deny is a common practice for insurers, signaling an urgent need for solutions that hold them accountable.”

The alliance is launching Cancer Care Denied, a grassroots campaign to shift the balance of power and give physicians and patients more say in cancer care. They are calling on insurance commissioners in all 50 states to adopt and enforce principles of a Cancer Patients’ Timely Treatment Bill of Rights. The Bill of Rights calls for:

  • Fair, timely and appropriate access to doctor-recommended cancer treatment;
  • Enforcement mechanisms executed by insurance commissioners, including automatic approvals if insurers fail to meet timelines and meaningful fines for repeated failure to provide fair, appropriate approvals; and
  • The same rights for cancer patients covered by employer self-funded plans.

The failure of insurers to abide by these simple principles imposes tremendous physical and financial stress on patients, according to the alliance. The alliance’s report includes detailed accounts from a number of cancer patients affected by the disproportionate power wielded by health insurers over patients and their physicians, including: 

“By adopting and enforcing common-sense principles, state insurance commissioners can take an important step toward repairing the broken system cancer patients face when they and their doctors are fighting for the best chance at survival and the highest quality of life,” added Smith. “Cancer patients should be fighting cancer, not their insurance companies.”

Proton therapy is a U.S. Food and Drug Administration (FDA)-cleared treatment, often approved for pediatric and Medicare patients, that allows physicians to precisely control and conform the bulk of its cancer-fighting proton energy field on cancerous cells. This minimizes extraneous radiation dose to healthy tissues, preserving organ function and potentially reducing harmful side effects. Proton therapy is medically necessary for many patients suffering from a variety of cancers.

For more information: www.allianceforprotontherapy.org

Related Content

Henry Ford Hospital's ViewRay MRIdian linear accelerator system allows real-time MRI-guided radiotherapy.

Henry Ford Hospital's ViewRay MRIdian linear accelerator system allows real-time MRI-guided radiotherapy.

Feature | Henry Ford Hospital | May 21, 2019 | Dave Fornell, Editor
Henry Ford Hospital thought leaders regularly speak at the radiation oncology and radiology conferences about new res
Varian Acquiring Cancer Treatment Services International
News | Radiation Therapy | May 21, 2019
Varian Medical Systems announced it has entered into a definitive agreement to acquire India’s Cancer Treatment...
Videos | Radiation Therapy | May 21, 2019
This is a walk through of the ViewRay MRIdian MRI-guided radiotherapy system installed at ...
Partial Breast Irradiation Effective, Convenient Treatment Option for Low-Risk Breast Cancer
News | Radiation Therapy | May 20, 2019
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast...
New Method Improves Ability to Measure and Maximize Radiation Therapy Dose
News | Radiation Therapy | May 14, 2019
Delivering just the right dose of radiation for cancer patients is a delicate balance in their treatment regime....
Sponsored Content | Videos | Radiation Oncology | May 13, 2019
At ASTRO 2018, Accuray showcased new patient-fi
Radiotherapy After Chemo May Improve Survival in Advanced Hodgkin's Lymphoma Patients
News | Radiation Therapy | May 10, 2019
Patients with advanced Hodgkin's lymphoma who have large tumors at the time of diagnosis may benefit from radiotherapy...
IBA Partnering to Develop Advanced Digital Proton Therapy Technologies in Belgium
News | Proton Therapy | May 10, 2019
IBA (Ion Beam Applications SA) announced a research agreement with Skandionkliniken, Université Catholique de Louvain...
A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beam will ablate for a noninvasive pulmonary vein isolation procedure. Varian acquires, buys, purchases Cyberheart.

A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beams will ablate for a noninvasive pulmonary vein isolation procedure to treat an arrhythmia.

Feature | Radiation Therapy | May 10, 2019
May 10, 2019 — Radiation oncology vendor Varian announced it acquired the start-up company CyberHeart, which has deve